IDEMIA
27.4.2020 03:02:08 CEST | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, today announced the first deployment of MorphoWave ™ Compact in Japan to provide high security and convenience for businesses and the public.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200426005034/en/
The contactless fingerprint technology was installed in the new headquarters of Digital Garage, located in the famous Shibuya district in Tokyo. They are the first to experience such a fast, frictionless and seamless biometric access control in Japan, through this deployment conducted in collaboration with IDEMIA’s official value added partner JAPAN AEROSPACE CORPORATION (JAC). JAC also conducted the network configuration using MorphoWave ™ Compact to integrate with Digital Garage’s system.
The Shibuya headquarters’ 450 employees enjoy all the benefits of MorphoWave ™ Compact for office and floor access control. They can authenticate their biometrics by a touchless “wave” gesture of the hand within the MorphoWave ™ Compact reader, which ensures efficiency, convenience, speed and security. This is also a more hygienic verification method since the users’ fingers are not in contact with the biometric sensor, whether accessing the building and floor or being enrolled.
MorphoWave ™ Compact is a biometric reader equipped with 3D fingerprint technology powered by Artificial Intelligence (AI) that can scan four fingers in less than one second. The algorithms in the biometric system ensure high matching accuracy and it enables up to 100,000 users being identified by one device. In a broader view, MorphoWave ™ Compact eliminates the need for cards, remembering PINs, tailgating and importantly, the concern of multiple people touching a surface.
Nezu Nobuyoshi, Managing Director and Vice President of Sales in IDEMIA Japan said: “With the increasing number of access points in buildings and offices, having touchless 3D fingerprint authentication technology is increasingly important to achieve convenience and maximum security. As a leader in biometrics, we want to provide entities with an advanced biometric technology that is convenient to use and allows users to identify themselves without complications.”
A spokesperson from Digital Garage said: “We are proud to be the first in Japan to implement this touchless 3D fingerprint technology for biometric access control, which ensures accurate identification of our employees and visitors. IDEMIA’s technology is the ideal fit for us, thanks to its versatile and easy deployment, accuracy and reliability in fingerprint matching.”
-END-
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For further information, go to www.idemia.com / And follow @IdemiaGroup on Twitter
About Digital Garage
Digital Garage is engaged in two recurring businesses: the fintech business, which provides a package of various payment methods to e-commerce operators and face-to-face retailers, and the marketing business, which provides integrated solutions in the digital and real fields. In addition, it is developing investment and development businesses for promising companies around the world. In addition, in collaboration with our core partners, they operate DG Lab, an open innovation R&D organization. As a company that creates new "contexts" in the Internet age, they will connect various businesses and create innovative services.
About JAC
JAPAN AEROSPACE CORPORATION (JAC) has a history of more than 60 years and a core aerospace company of ITOCHU Group, providing unique and specialized services based on the concept of "only one" and "niche top". JAC offers value added "engineering and technical” services and propose business solutions, mainly relating to national security and social infrastructure along with improvement of safety, comfortability and affordability to the Japanese market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200426005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
